Literature DB >> 34108342

Factors Associated with Carotid Atherosclerosis and Achilles Tendon Thickness in Japanese Patients with Familial Hypercholesterolemia: A Subanalysis of the Familial Hypercholesterolemia Expert Forum (FAME) Study.

Masatsune Ogura1, Mariko Harada-Shiba1, Daisaku Masuda2,3, Hidenori Arai4, Hideaki Bujo5, Shun Ishibashi6, Hiroyuki Daida7, Nobuhiko Koga8, Shinichi Oikawa9, Shizuya Yamashita2,10,3.   

Abstract

AIMS: Familial hypercholesterolemia (FH) is characterized by high low-density lipoprotein (LDL) cholesterol levels, xanthomas including Achilles tendon thickening, and premature coronary artery disease (CAD). Carotid intima-media thickness (IMT) is a well-established surrogate marker for CAD in FH and Achilles tendon thickening is a specific physical finding in patients with FH. The objective of the present study was to identify factors associated with carotid IMT and Achilles tendon thickness in FH heterozygotes on lipid-lowering therapy. This study also aimed to examine the follow-up changes in carotid IMT and Achilles tendon thickness among them in the current real-world FH practice.
METHODS: The current study is a subanalysis of the Familial Hypercholesterolemia Expert Forum (FAME) Study. The severity of carotid atherosclerosis was assessed with the maximal and mean IMT using ultrasonography, and Achilles tendon thickness was measured using X-rays. The present study used 571 patients under medical treatment for heterozygous FH who had baseline measurements for maximal IMT (n=511), mean IMT (n=459), or Achilles tendon thickness (n=486). The IMT was measured annually, and Achilles tendon thickness was evaluated every two years.
RESULTS: Higher LDL cholesterol (LDL-C) level and lower HDL cholesterol (HDL-C) level were associated with greater maximal and mean IMT as well as greater Achilles tendon thickness. Achilles tendon thickness tended to be greater in patients who had a smoking history than in never-smokers. Maximal IMT and Achilles tendon thickness were significantly greater in patients with CAD than in those without. Additionally, lower HDL-C level and hypertension were associated with higher values of maximal and mean IMT, suggesting the importance of comprehensive risk management including reduced HDL-C and blood pressure control in FH care. In longitudinal observations, percentage changes in maximal IMT and mean IMT gradually increased during the observation period. In contrast, percentage changes in Achilles tendon thickness became progressively thinner throughout the observation period.
CONCLUSIONS: We found a positive association between LDL-C levels and severity of carotid atherosclerosis in heterozygous FH patients on treatment. This observation suggests the insufficiency of lipid-lowering therapy and the presence of therapeutic inertia among clinicians in the real-world FH practice.

Entities:  

Keywords:  Achilles tendon thickness; Carotid intima-media thickness; Drug treatment; Familial hypercholesterolemia; LDL-cholesterol

Mesh:

Substances:

Year:  2021        PMID: 34108342      PMCID: PMC9174085          DOI: 10.5551/jat.62925

Source DB:  PubMed          Journal:  J Atheroscler Thromb        ISSN: 1340-3478            Impact factor:   4.394


  43 in total

1.  Molecular genetic epidemiology of homozygous familial hypercholesterolemia in the Hokuriku district of Japan.

Authors:  Hiroshi Mabuchi; Atsushi Nohara; Tohru Noguchi; Junji Kobayashi; Masa-Aki Kawashiri; Hayato Tada; Chiaki Nakanishi; Mika Mori; Masakazu Yamagishi; Akihiro Inazu; Junji Koizumi
Journal:  Atherosclerosis       Date:  2010-11-13       Impact factor: 5.162

2.  Contemporary Trends in the Management and Outcomes of Patients With Familial Hypercholesterolemia in Canada: A Prospective Observational Study.

Authors:  Liam R Brunham; Lubomira Cermakova; Terry Lee; Ida Priecelova; Karine Alloul; Marilyn de Chantal; Gordon A Francis; Jiri Frohlich
Journal:  Can J Cardiol       Date:  2016-09-03       Impact factor: 5.223

3.  Estimated Prevalence of Heterozygous Familial Hypercholesterolemia in Patients With Acute Coronary Syndrome.

Authors:  Hirotoshi Ohmura; Yoshifumi Fukushima; Atsushi Mizuno; Koichiro Niwa; Yohei Kobayashi; Toshiaki Ebina; Kazuo Kimura; Shun Ishibashi; Hiroyuki Daida
Journal:  Int Heart J       Date:  2017-01-24       Impact factor: 1.862

4.  Smoking influences the atherogenic potential of low-density lipoprotein.

Authors:  E Scheffler; E Wiest; J Woehrle; I Otto; I Schulz; L Huber; R Ziegler; H A Dresel
Journal:  Clin Investig       Date:  1992 Mar-Apr

5.  Regression of carotid and femoral artery intima-media thickness in familial hypercholesterolemia: treatment with simvastatin.

Authors:  Pernette R W de Sauvage Nolting; Eric de Groot; Aeilko H Zwinderman; Rudolf J A Buirma; Mieke D Trip; John J P Kastelein
Journal:  Arch Intern Med       Date:  2003 Aug 11-25

6.  Influence of HDL cholesterol on preclinical carotid atherosclerosis in familial hypercholesterolemia.

Authors:  Mireia Junyent; Montserrat Cofán; Isabel Núñez; Rosa Gilabert; Daniel Zambón; Emilio Ros
Journal:  Arterioscler Thromb Vasc Biol       Date:  2006-03-23       Impact factor: 8.311

7.  Association Between Cholesterol Efflux Capacity and Atherosclerotic Cardiovascular Disease in Patients With Familial Hypercholesterolemia.

Authors:  Masatsune Ogura; Mika Hori; Mariko Harada-Shiba
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-11-05       Impact factor: 8.311

Review 8.  Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients.

Authors:  Daniel Keene; Clare Price; Matthew J Shun-Shin; Darrel P Francis
Journal:  BMJ       Date:  2014-07-18

9.  Long-Term Effect of Pravastatin on Carotid Intima-Media Complex Thickness: The J-STARS Echo Study (Japan Statin Treatment Against Recurrent Stroke).

Authors:  Masatoshi Koga; Kazunori Toyoda; Kazuo Minematsu; Masahiro Yasaka; Yoji Nagai; Shiro Aoki; Tomohisa Nezu; Naohisa Hosomi; Tatsuo Kagimura; Hideki Origasa; Kenji Kamiyama; Rieko Suzuki; Toshiho Ohtsuki; Hirofumi Maruyama; Kazuo Kitagawa; Shinichiro Uchiyama; Masayasu Matsumoto
Journal:  Stroke       Date:  2017-11-30       Impact factor: 7.914

10.  Probucol Trial for Secondary Prevention of Atherosclerotic Events in Patients with Coronary Heart Disease (PROSPECTIVE).

Authors:  Shizuya Yamashita; Hidenori Arai; Hideaki Bujo; Daisaku Masuda; Tohru Ohama; Toshiyuki Ishibashi; Koji Yanagi; Yasuji Doi; Satoshi Nakagawa; Koichi Yamashiro; Kenichiro Tanabe; Toru Kita; Masunori Matsuzaki; Yasushi Saito; Masanori Fukushima; Yuji Matsuzawa
Journal:  J Atheroscler Thromb       Date:  2020-04-24       Impact factor: 4.928

View more
  2 in total

Review 1.  How Can We Identify Very High-Risk Heterozygous Familial Hypercholesterolemia?

Authors:  Yu Kataoka; Sayaka Funabashi; Takahito Doi; Mariko Harada-Shiba
Journal:  J Atheroscler Thromb       Date:  2022-01-13       Impact factor: 4.394

2.  Prospective Registry Study of Primary Dyslipidemia (PROLIPID): Rationale and Study Design.

Authors:  Hayato Tada; Tomoyuki Kurashina; Masatsune Ogura; Misa Takegami; Yoshihiro Miyamoto; Hidenori Arai; Mariko Harada-Shiba; Shun Ishibashi
Journal:  J Atheroscler Thromb       Date:  2021-10-22       Impact factor: 4.394

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.